Rimonabant was the first CB1 antagonist approved by the European Medicines Agency for the treatment of obesity, but it was later withdrawn from the market due to severe psychiatric side effects, including depression, anxiety, and suicidal ideation [69]. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.